|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schuette W: Treatment of brain metastases
from lung cancer: Chemotherapy. Lung Cancer. 45(Suppl 2):
S253–S257. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Langer CJ and Mehta MP: Current management
of brain metastases, with a focus on systemic options. J Clin
Oncol. 23:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patchell RA, Tibbs PA, Walsh JW, Dempsey
RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS and Young
B: A randomized trial of surgery in the treatment of single
metastases to the brain. N Engl J Med. 322:494–500. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patchell RA, Tibbs PA, Regine WF, Dempsey
RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA and Young B:
Postoperative radiotherapy in the treatment of single metastases to
the brain: A randomized trial. JAMA. 280:1485–1489. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hazard LJ, Jensen RL and Shrieve DC: Role
of stereotactic radiosurgery in the treatment of brain metastases.
Am J Clin Oncol. 28:403–410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin H, Pan F, Li J, Zhang X, Liang H and
Ruan Z: Whole brain radiotherapy plus concurrent chemotherapy in
non-small cell lung cancer patients with brain metastases: A
meta-analysis. PLoS One. 9:e1114752014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsiung CY, Leung SW, Wang CJ, Lo SK, Chen
HC, Sun LM and Fang FM: The prognostic factors of lung cancer
patients with brain metastases treated with radiotherapy. J
Neurooncol. 36:71–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lagerwaard FJ, Levendag PC, Nowak PJ,
Eijkenboom WM, Hanssens PE and Schmitz PI: Identification of
prognostic factors in patients with brain metastases: A review of
1292 patients. Int J Radiat Oncol Biol Phys. 43:795–803. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Armstrong JG, Wronski M, Galicich J, Arbit
E, Leibel SA and Burt M: Postoperative radiation for lung cancer
metastatic to the brain. J Clin Oncol. 12:2340–2344.
1994.PubMed/NCBI
|
|
11
|
Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X
and Chen LK: Pemetrexed and cisplatin combination with concurrent
whole brain radiotherapy in patients with brain metastases of lung
adenocarcinoma: A single-arm phase II clinical trial. J Neurooncol.
112:461–466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kataoka K, Uejima T, Niiyama K, Kuroda R,
Arita N, Ioku M, Yamada K, Taneda M and Hayakawa T: Long survival
after removal of a huge brain tumor which had metastasized from a
lung cancer: Case report. Neurological Surgery. 22:339–341.
1994.(In Japanese). PubMed/NCBI
|
|
13
|
Ettinger DS, Akerley W, Borghaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: National comprehensive cancer network:
Non-small cell lung cancer, version 2. 2013. J Natl Compr Canc
Netw. 11:645–653; quiz 653. 2013.PubMed/NCBI
|
|
14
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ceresoli GL, Cappuzzo F, Gregorc V,
Bartolini S, Crinò L and Villa E: Gefitinib in patients with brain
metastases from non-small-cell lung cancer: A prospective trial.
Ann Oncol. 15:1042–1047. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Park SJ, Kim HT, Lee DH, Kim KP, Kim SW,
Suh C and Lee JS: Efficacy of epidermal growth factor receptor
tyrosine kinase inhibitors for brain metastasis in non-small cell
lung cancer patients harboring either exon 19 or 21 mutation. Lung
Cancer. 77:556–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jung YH, Han CW, Jung YD, Cho YY and Han
DJ: Complete remission of brain metastases in non-small cell lung
cancer patients harboring an EGFR mutation treated with tyrosine
kinase inhibitor without radiotherapy: A report of 3 cases. Case
Rep Oncol. 7:149–154. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Iuchi T, Shingyoji M, Sakaida T, Hatano K,
Nagano O, Itakura M, Kageyama H, Yokoi S, Hasegawa Y, Kawasaki K
and Iizasa T: Phase II trial of gefitinib alone without radiation
therapy for Japanese patients with brain metastases from
EGFR-mutant lung adenocarcinoma. Lung Cancer. 82:282–287. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun X and Zheng Y: Retreatment with
icotinib in a patient with metastatic lung adenocarcinoma. Tumori.
99:e124–e126. 2013.PubMed/NCBI
|
|
20
|
Zhao J, Chen M, Zhong W, Zhang L, Li L,
Xiao Y, Nie L, Hu P and Wang M: Cerebrospinal fluid concentrations
of gefitinib in patients with lung adenocarcinoma. Clin Lung
Cancer. 14:188–193. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan Y, Tan C, Li M, Shen H, Fang X, Hu Y
and Ma S: Activity of pemetrexed and high-dose gefitinib in an
EGFR-mutated lung adenocarcinoma with brain and leptomeningeal
metastasis after response to gefitinib. World J Surg Oncol.
10:2352012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X,
Zhu G, Ji Q and Peng Y: EGFR mutation status and its impact on
survival of Chinese non-small cell lung cancer patients with brain
metastases. Tumour Biol. 35:2437–2444. 2014. View Article : Google Scholar : PubMed/NCBI
|
